CliffBio
small molecule

VASOPRESSIN

VASOPRESSIN

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameVASOPRESSIN
Active ingredientVASOPRESSIN
Strength20UNITS/100ML (0.2UNITS/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2023
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VASOPRESSIN patent cliff — loss of exclusivity — | CliffBio